Search Within

Achim Jungbluth

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (17)
  2. Meeting Abstract (9)
Groups
  1. Department of Pathology and Laboratory Medicine (26)
  2. Epidemiology and Biostatistics (26)
  3. Biostatistics Service (22)
  4. Department of Medicine (19)
  5. GSK Faculty (18)
  6. Solid Tumor Oncology Division (17)

More Groups

People
  1. Lloyd Old (8)
  2. Katherine Panageas (7)
  3. Denise Frosina (6)
  4. Marc Ladanyi (6)
  5. Jedd Wolchok (5)
  6. Klaus Busam (5)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (5)

More Years

Publications
  1. Journal of Clinical Oncology (4)
  2. Modern Pathology (4)
  3. Cancer Discovery (2)
  4. Proceedings of the National Academy of Sciences of the United States of America (2)
  5. American Journal of Surgical Pathology (1)
  6. Blood (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (5)
  2. American Association for Cancer Research (4)
  3. Nature Research (4)
  4. American Society of Hematology (2)
  5. Elsevier Science, Inc. (2)
  6. National Academy of Sciences (2)

More Publishers

Results (26)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in patients with T- and/or NK-cell lymphoma
    Journal Article

    Liu, Y.; Sardana, R.; Nemirovsky, D.; Frosina, D.; Jungbluth, A.; Johnson, W. T.; Vardhana, S.; Arcila, M.; Horwitz, S. M.; Derkach, A.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Assessing PD-L1 without a biopsy and through PD-L1 PET imaging with 18F-BMS-986229
    Meeting Abstract

    Postow, M. A.; Mauguen, A.; Frosina, D.; Jungbluth, A. A.; Busam, K. J.; Pandit Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • PD-L1 expression in metaplastic breast carcinoma using the PD-L1 SP142 assay and concordance among PD-L1 immunohistochemical assays
    Journal Article

    Grabenstetter, A.; Jungbluth, A. A.; Frosina, D.; Hoda, R.; Dos Anjos, C. H.; Patil, S.; Sevilimedu, V.; Weigelt, B.; Reis-Filho, J. S.; Zhang, H.; more...
    American Journal of Surgical Pathology (2021)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract
    Journal Article

    Sarfaty, M.; Whiting, K.; Teo, M. Y.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; Jungbluth, A. A.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma
    Journal Article

    Muller, S.; Lai, W. V.; Adusumilli, P. S.; Desmeules, P.; Frosina, D.; Jungbluth, A.; Ni, A.; Eguchi, T.; Travis, W. D.; Ladanyi, M.; more...
    Modern Pathology (2020)

    Fulltext@MSK | Save
  • Radiogenomics analysis of intratumor heterogeneity in a patient with high-grade serous ovarian cancer
    Journal Article

    Weigelt, B.; Vargas, H. A.; Selenica, P.; Geyer, F. C.; Mazaheri, Y.; Blecua, P.; Conlon, N.; Hoang, L. N.; Jungbluth, A. A.; Snyder, A.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Patient-driven discovery, therapeutic targeting, and post-clinical validation of a novel AKT1 fusion-driven cancer
    Journal Article

    Slotkin, E. K.; Diolaiti, D.; Shukla, N. N.; Dela Cruz, F. S.; Clark, J. J.; Gundem, G.; Yellapantula, V. D.; Levine, M. F.; You, D.; Ma, P.; more...
    Cancer Discovery (2019)

    Fulltext@MSK | Save
  • VISTA is highly expressed in malignant pleural mesothelioma (MPM) and independent of PD-L1 expression
    Meeting Abstract

    Zauderer, M.; Muller, S.; Lai, W.; Ni, A.; Jungbluth, A.; Ginsberg, M.; Daly, R.; Hellmann, M.; Ladanyi, M.; Sauter, J.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Integrative molecular characterization of malignant pleural mesothelioma
    Journal Article

    Hmeljak, J.; Sanchez-Vega, F.; Hoadley, K. A.; Shih, J.; Stewart, C.; Heiman, D.; Tarpey, P.; Danilova, L.; Drill, E.; Gibb, E. A.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Pulmonary BRG1 (SMARCA4)-deficient undifferentiated neoplasms represent an exceptionally aggressive type of sarcomatoid carcinoma: Clinicopathologic and genomic evidence supports a link to non-small cell carcinoma
    Meeting Abstract

    Montecalvo, J.; Alex, D.; Ptashkin, R.; Ni, A.; Sauter, J. L.; Chang, J.; Jungbluth, A.; Beras, A.; Namakydoust, A.; Rudin, C.; more...
    Modern Pathology (2018)

    Fulltext@MSK | Save